DYRK1A and Alzheimer disease: In addition, we and others have reported that pharmacological DYRK1A inhibition (e.g., with KVN93) ameliorates cognitive dysfunction and AD pathology in 3xTg AD mice and Aβ-overexpressing 5xFAD mice (22, 23).